Daily Medication Pearl: Lifitegrast Ophthalmic Solution (Xiidra)


Lifitegrast ophthalmic solution (Xiidra) 5% is indicated for the treatment of the signs and symptoms of dry eye disease.

Medication Pearl of the Day: Lifitegrast Ophthalmic Solution (Xiidra)

Indication: Lifitegrast ophthalmic solution (Xiidra) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED).


  • Dosing: One drop twice daily in each eye (approximately 12 hours apart).
  • Dosage forms: Ophthalmic solution containing lifitegrast 5% (50 mg/mL).
  • Adverse events: The most common adverse reactions (incidence 5%-25%) following the use of Xiidra were instillation site irritation, dysgeusia, and decreased visual acuity.
  • Mechanism of action: Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1).
  • Manufacturer: Shire


label (fda.gov)

xiidra image - Google Search

Related Videos
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image Credit: Pixel-Shot | stock.adobe.com
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.